CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Aclaris Therapeutics Inc - ACRS CFD

    Market is not available at the moment

    Market information is presented
    as of 2023-09-21

    • Summary
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Aclaris Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 14.01
    Open* 14.02
    1-Year Change* -1.68%
    Day's Range* 13.84 - 14.36
    52 wk Range 5.77-18.96
    Average Volume (10 days) 943.88K
    Average Volume (3 months) 13.87M
    Market Cap 535.92M
    P/E Ratio -100.00K
    Shares Outstanding 70.79M
    Revenue 31.17M
    EPS -1.55
    Dividend (Yield %) N/A
    Beta 0.66
    Next Earnings Date Nov 6, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    Date Close Change Change (%) Open High Low
    Jun 29, 2022 14.32 0.74 5.45% 13.58 14.37 13.50
    Jun 28, 2022 14.01 -0.96 -6.41% 14.97 15.26 13.98
    Jun 27, 2022 15.06 0.68 4.73% 14.38 15.72 14.38
    Jun 24, 2022 14.41 -1.42 -8.97% 15.83 16.16 14.17
    Jun 23, 2022 15.81 0.28 1.80% 15.53 16.17 15.13
    Jun 22, 2022 15.43 0.01 0.06% 15.42 16.16 15.41
    Jun 21, 2022 15.93 0.35 2.25% 15.58 16.52 15.58
    Jun 17, 2022 15.57 0.97 6.64% 14.60 15.84 14.60
    Jun 16, 2022 14.76 0.77 5.50% 13.99 14.88 13.99
    Jun 15, 2022 14.72 0.89 6.44% 13.83 14.80 13.80
    Jun 14, 2022 13.95 1.16 9.07% 12.79 14.00 12.65
    Jun 13, 2022 12.91 -0.88 -6.38% 13.79 13.99 12.41
    Jun 10, 2022 14.39 -0.22 -1.51% 14.61 14.90 14.17
    Jun 9, 2022 15.04 0.06 0.40% 14.98 15.48 14.98
    Jun 8, 2022 15.42 0.41 2.73% 15.01 15.86 15.01
    Jun 7, 2022 15.39 1.36 9.69% 14.03 15.45 14.03
    Jun 6, 2022 14.71 -0.02 -0.14% 14.73 14.94 14.44
    Jun 3, 2022 14.70 0.48 3.38% 14.22 14.90 14.08
    Jun 2, 2022 14.41 1.06 7.94% 13.35 14.94 13.35
    Jun 1, 2022 13.32 0.66 5.21% 12.66 13.43 12.59

    Aclaris Therapeutics Inc Events

    Time (UTC) Country Event
    Monday, November 6, 2023

    Time (UTC)

    13:30

    Country

    US

    Event

    Q3 2023 Aclaris Therapeutics Inc Earnings Release
    Q3 2023 Aclaris Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    Wednesday, February 21, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Aclaris Therapeutics Inc Earnings Release
    Q4 2023 Aclaris Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 29.752 6.761 6.482 4.227 6.151
    Revenue 29.752 6.761 6.482 4.227 6.151
    Total Operating Expense 119.606 96.484 57.394 115.285 90.931
    Selling/General/Admin. Expenses, Total 25.133 23.619 20.53 27.827 25.761
    Research & Development 77.813 43.813 31.731 64.899 60.841
    Operating Income -89.854 -89.723 -50.912 -111.058 -84.78
    Other, Net 2.946 -1.142 -0.424 -2.484 2.676
    Net Income Before Taxes -86.908 -90.865 -51.336 -113.542 -82.104
    Net Income After Taxes -86.908 -90.865 -51.154 -113.542 -82.104
    Net Income Before Extra. Items -86.908 -90.865 -51.154 -113.542 -82.104
    Net Income -86.908 -90.865 -51.015 -161.354 -132.738
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -86.908 -90.865 -51.154 -113.542 -82.104
    Income Available to Common Incl. Extra. Items -86.908 -90.865 -51.015 -161.354 -132.738
    Diluted Net Income -86.908 -90.865 -51.015 -161.354 -132.738
    Diluted Weighted Average Shares 65.2139 56.7306 42.5393 41.3239 32.9098
    Diluted EPS Excluding Extraordinary Items -1.33266 -1.60169 -1.20251 -2.74761 -2.49482
    Dividends per Share - Common Stock Primary Issue
    Diluted Normalized EPS -1.26059 -1.17267 -1.20251 -2.29983 -2.49482
    Cost of Revenue, Total 11.96 4.713 5.133 4.055 4.329
    Gross Profit 17.792 2.048 1.349 0.172 1.822
    Total Extraordinary Items 0 0 0.139 -47.812 -50.634
    Depreciation / Amortization 0 0
    Unusual Expense (Income) 4.7 24.339 0 18.504 0
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 1.869 2.528 7.753 19.018 1.528
    Revenue 1.869 2.528 7.753 19.018 1.528
    Cost of Revenue, Total 1.592 1.869 1.514 8.223 1.068
    Gross Profit 0.277 0.659 6.239 10.795 0.46
    Total Operating Expense 33.684 32.446 36.832 39.892 22.522
    Selling/General/Admin. Expenses, Total 8.317 8.79 7.146 5.813 6.075
    Research & Development 25.275 22.587 21.072 23.656 18.779
    Unusual Expense (Income) -1.5 -0.8 7.1 2.2 -3.4
    Operating Income -31.815 -29.918 -29.079 -20.874 -20.994
    Other, Net 2.246 1.758 1.444 0.922 0.462
    Net Income Before Taxes -29.569 -28.16 -27.635 -19.952 -20.532
    Net Income After Taxes -29.569 -28.16 -27.635 -19.952 -20.532
    Net Income Before Extra. Items -29.569 -28.16 -27.635 -19.952 -20.532
    Total Extraordinary Items 0
    Net Income -29.569 -28.16 -27.635 -19.952 -20.532
    Income Available to Common Excl. Extra. Items -29.569 -28.16 -27.635 -19.952 -20.532
    Income Available to Common Incl. Extra. Items -29.569 -28.16 -27.635 -19.952 -20.532
    Diluted Net Income -29.569 -28.16 -27.635 -19.952 -20.532
    Diluted Weighted Average Shares 70.6335 66.8728 66.7018 66.6753 65.99
    Diluted EPS Excluding Extraordinary Items -0.41863 -0.4211 -0.41431 -0.29924 -0.31114
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.43986 -0.43306 -0.30786 -0.26625 -0.36266
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 231.55 205.032 57.493 83.803 179.499
    Cash and Short Term Investments 217.571 191.414 54.131 75.015 167.972
    Cash & Equivalents 45.277 27.349 22.063 35.937 57.019
    Short Term Investments 172.294 164.065 32.068 39.078 110.953
    Prepaid Expenses 13.495 12.995 2.59 3.118 4.802
    Total Assets 254.596 251.211 70.784 98.297 275.566
    Property/Plant/Equipment, Total - Net 3.779 4.772 5.783 7.203 2.287
    Property/Plant/Equipment, Total - Gross 10.374 9.968 9.517 9.749 3.609
    Accumulated Depreciation, Total -6.595 -5.196 -3.734 -2.546 -1.322
    Long Term Investments 12.242 34.242
    Other Long Term Assets, Total 0.052 0.117 0.385 0.092 68.003
    Total Current Liabilities 21.938 22.931 14.874 22.432 27.342
    Accounts Payable 10.351 9.985 5.254 9.917 14.755
    Accrued Expenses 5.979 5.082 4.574 4.015 6.071
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 5.608 7.864 5.046 8.389 6.374
    Total Liabilities 56.975 53.87 33.134 28.385 60.442
    Total Long Term Debt 0 0 10.653 0.021 29.914
    Other Liabilities, Total 34.67 30.572 7.24 5.383 2.637
    Total Equity 197.621 197.341 37.65 69.912 215.124
    Redeemable Preferred Stock 0 0 0 0 0
    Common Stock 0.001 0.001 0.00045 0.00042 0
    Additional Paid-In Capital 880.832 792.971 542.286 523.505 507.366
    Retained Earnings (Accumulated Deficit) -682.315 -595.407 -504.542 -453.527 -292.173
    Other Equity, Total -0.897 -0.224 -0.09445 -0.06642 -0.069
    Total Liabilities & Shareholders’ Equity 254.596 251.211 70.784 98.297 275.566
    Total Common Shares Outstanding 66.6887 61.2285 45.1093 41.4856 41.2107
    Total Receivables, Net 0.484 0.623 0.772 0.704 0.563
    Accounts Receivable - Trade, Net 0.484 0.623 0.772 0.704 0.563
    Goodwill, Net 0 18.504
    Intangibles, Net 6.973 7.048 7.123 7.199 7.273
    Current Port. of LT Debt/Capital Leases 0 0.111 0.142
    Deferred Income Tax 0.367 0.367 0.367 0.549 0.549
    Total Inventory 0 0
    Other Current Assets, Total 4.966 6.162
    Long Term Debt 0 10.653 0 29.914
    Capital Lease Obligations 0 0.021
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 184.361 231.55 256.573 259.354 190.881
    Cash and Short Term Investments 170.803 217.571 248.062 248.603 179.622
    Cash & Equivalents 44.722 45.277 61.653 68.264 36.342
    Short Term Investments 126.081 172.294 186.409 180.339 143.28
    Total Receivables, Net 0.686 0.484 0.597 0.637 0.633
    Accounts Receivable - Trade, Net 0.686 0.484 0.597 0.637 0.633
    Prepaid Expenses 12.872 13.495 7.914 10.114 10.626
    Total Assets 229.705 254.596 267.632 277.976 226.527
    Property/Plant/Equipment, Total - Net 4.546 3.779 4.021 4.343 4.531
    Property/Plant/Equipment, Total - Gross 11.528 10.374 10.25 10.217 10.056
    Accumulated Depreciation, Total -6.982 -6.595 -6.229 -5.874 -5.525
    Intangibles, Net 6.954 6.973 6.992 7.011 7.03
    Long Term Investments 33.602 12.242 0 7.221 23.955
    Other Long Term Assets, Total 0.242 0.052 0.046 0.047 0.13
    Total Current Liabilities 18.258 21.938 19.789 16.217 16.726
    Accounts Payable 8.19 10.351 7.667 5.703 8.121
    Accrued Expenses 3.237 5.979 4.596 3.626 2.9
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 6.831 5.608 7.526 6.888 5.705
    Total Liabilities 52.895 56.975 47.794 42.224 46.328
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt 0
    Deferred Income Tax 0.367 0.367 0.367 0.367 0.367
    Other Liabilities, Total 34.27 34.67 27.638 25.64 29.235
    Total Equity 176.81 197.621 219.838 235.752 180.199
    Redeemable Preferred Stock 0 0 0 0 0
    Common Stock 0.001 0.001 0.001 0.001 0.001
    Additional Paid-In Capital 887.638 880.832 875.982 871.805 795.366
    Retained Earnings (Accumulated Deficit) -710.475 -682.315 -654.68 -634.728 -614.196
    Other Equity, Total -0.354 -0.897 -1.465 -1.326 -0.972
    Total Liabilities & Shareholders’ Equity 229.705 254.596 267.632 277.976 226.527
    Total Common Shares Outstanding 67.206 66.6887 66.6796 66.6676 61.7375
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -86.908 -90.865 -51.015 -161.354 -132.738
    Cash From Operating Activities -67.567 -52.134 -38.633 -96.445 -100.811
    Cash From Operating Activities 0.797 0.923 1.324 6.409 1.879
    Non-Cash Items 19.739 39.151 13.6 61.203 20.61
    Changes in Working Capital -1.195 -1.343 -2.36 -2.703 9.438
    Cash From Investing Activities 12.628 -167.632 6.387 105.679 9.367
    Capital Expenditures -0.605 -0.308 -0.453 -1.613 -1.356
    Other Investing Cash Flow Items, Total 13.233 -167.324 6.84 107.292 10.723
    Cash From Financing Activities 72.867 225.052 18.372 -30.316 128.261
    Issuance (Retirement) of Stock, Net 72.901 239.659 7.807 0.207 100.782
    Net Change in Cash 17.928 5.286 -13.874 -21.082 36.817
    Deferred Taxes 0 -0.182 0 0
    Financing Cash Flow Items -0.034 -3.124 -0.211 28.127
    Issuance (Retirement) of Debt, Net -11.483 10.776 -30.523 -0.648
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -28.16 -86.908 -59.273 -39.321 -18.789
    Cash From Operating Activities -26.353 -67.567 -48.452 -40.635 -20.969
    Cash From Operating Activities 0.198 0.797 0.607 0.414 0.208
    Non-Cash Items 6.006 19.739 7.826 1.438 1.146
    Changes in Working Capital -4.397 -1.195 2.388 -3.166 -3.534
    Cash From Investing Activities 25.798 12.628 9.926 8.709 29.932
    Capital Expenditures -0.553 -0.605 -0.5 -0.35 -0.164
    Other Investing Cash Flow Items, Total 26.351 13.233 10.426 9.059 30.096
    Cash From Financing Activities 0 72.867 72.83 72.841 0.03
    Financing Cash Flow Items 0 -0.034 -0.034 -0.023 -0.007
    Issuance (Retirement) of Stock, Net 0 72.901 72.864 72.864 0.037
    Issuance (Retirement) of Debt, Net 0
    Net Change in Cash -0.555 17.928 34.304 40.915 8.993
    Deferred Taxes

    Aclaris Therapeutics Inc Company profile

    About Aclaris Therapeutics Inc

    Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing drug candidates for immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. It is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Aclaris Therapeutics Inc revenues increased 4% to $6.8M. Net loss before extraordinary items increased 78% to $90.9M. Revenues reflect Therapeutics segment increase of 34% to $932K, Contract Research segment increase of 1% to $13.4M. Higher net loss reflects Therapeutics segment loss increase from $31.5M to $67.7M, Corporate segment loss increase of 16% to $20.6M.

    Industry: Biotechnology & Medical Research (NEC)

    640 Lee Rd Ste 200
    WAYNE
    PENNSYLVANIA 19087-5636
    US

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    BTC/USD

    26,680.30 Price
    +0.190% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    Oil - Crude

    89.95 Price
    +0.690% 1D Chg, %
    Long position overnight fee 0.0349%
    Short position overnight fee -0.0568%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    ETH/USD

    1,596.06 Price
    +0.400% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    XRP/USD

    0.52 Price
    +0.670% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading